Ontology highlight
ABSTRACT:
SUBMITTER: Mackiewicz J
PROVIDER: S-EPMC5885075 | biostudies-other | 2018 Mar
REPOSITORIES: biostudies-other
Mackiewicz Jacek J Mackiewicz Andrzej A
Contemporary oncology (Poznan, Poland) 20180305 1A
The treatment landscape in advanced melanoma is changing dramatically with the approval of new drugs. Vemurafenib was the first approved targeted agent for the treatment of <i>BRAF</i>-mutant advanced melanoma. However, treatment with a BRAF inhibitor is linked with acquired resistance occurring in half of the patients after approximately six months. Combination of MEK and BRAF inhibitor therapy results in extension of the time to resistance, translating into longer overall survival of treated p ...[more]